A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies
Year: 2012
Type: article
Abstract: Antibody PG9 is a prototypical member of a class of V1/V2-directed antibodies that effectively neutralizes diverse strains of HIV-1. We analyzed strain-specific resistance to PG9 using sequence and structural information. For multiply resistant strains, mutations in a short segment of V1/V2 resulted in gain of sensitivity to PG9 and related V1/V2 neutralizing antibodies, suggesting both a common mechanism of HIV-1 resistance to and a common mode of recognition by this class of antibodies.
Source: Journal of Virology
DOI: 10.1128/jvi.00696-12
Institutions: National Institutes of Health, National Institute of Allergy and Infectious Diseases, Vaccine Research Center, Duke University, Duke Medical Center, Scripps Research Institute, Harvard University, Ragon Institute of MGH, MIT and Harvard, Massachusetts Institute of Technology, International AIDS Vaccine Initiative
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2103360085
